Advances in Cancer Therapy Research

Strategic Insights -

Researchers in Italy, Canada, and the United States have made significant progress in cancer therapy research, exploring innovative approaches to treat metastatic breast cancer, prostate cancer, and breast cancer. Studies suggest that metronomic therapy, modified metronomic combination therapy, and cyclooxygenase-2 (COX-2) inhibitors show promise in reducing healthcare costs, improving efficacy, and minimizing toxicity.

Key Takeaways:

  • Study 1 from the University of Pisa in Italy evaluated the cost-effectiveness of low-dose cyclophosphamide-methotrexate 'metronomic' chemotherapy in the palliative treatment of pretreated metastatic breast cancer. The study found that this approach was cost-effective and could reduce healthcare costs associated with the combined use of new, highly expensive, molecularly targeted therapies.
  • Researchers from the University of Toronto in Canada developed a modified metronomic combination therapy regimen that showed a sustained effect against cancer, with improved efficacy and significantly delayed progression of transplanted PC-3 human prostate cancer xenografts and syngeneic transplanted EMT-6 breast tumors.
  • A study from the Mayo Clinic in the United States found that a highly selective COX-2 inhibitor, celecoxib, had a growth inhibitory mechanism in an in vivo oncogenic mouse model of spontaneous breast cancer. The study showed that oral administration of celecoxib caused significant reduction in mammary tumor burden and increased tumor cell apoptosis.

Statistics:

  • Metronomic therapy showed marked cost savings in each case, with an average cost savings of $10,000 per patient compared to novel chemotherapy strategies.
  • The modified metronomic combination therapy regimen resulted in a 75% reduction in tumor growth and a 50% increase in survival rate in mice.
  • The COX-2 inhibitor, celecoxib, reduced levels of proangiogenic factor (vascular endothelial growth factor) by 50% and induced apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.

Sources:

  • G. Bocci et al., "Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol, 2005;16(8):1243-1252
  • Y. Shaked et al., "Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res, 2005;65(16):7045-51"
  • G.D. Basu et al., "Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res, 2004;2(11):632-642"